Industry

USFDA issues Form 483 with one observation to Aurobindo Unit IV: Andhra Pradesh

The inspection, which took place from September 13 to September 19, culminated in the issuance of a 'Form 483', outlining a single procedural observation.

The Health Master

October 10, 2023

259

Table of Contents

Last Updated on October 9, 2024 by The Health Master

Form 483

Form 483: In a recent development, Aurobindo Pharma Ltd.‘s subsidiary, APL Healthcare Ltd., faced scrutiny from the United States Food and Drug Administration (USFDA) during an inspection of its Unit IV formulation manufacturing facility in Andhra Pradesh.

Follow us on WhtasApp Channel

The inspection, which took place from September 13 to September 19, culminated in the issuance of a ‘Form 483‘, outlining a single procedural observation.

This article delves into the specifics of the observation and its potential implications for Aurobindo Pharma.

Understanding the Form 483 Observation

A ‘Form 483’ is a critical document issued by the USFDA when inspectors identify conditions that could potentially breach the Food, Drug, and Cosmetic Act and Related Acts.

In this instance, the observation was related to procedural matters, indicating a need for corrective action.

Click for more articles on USFDA

Nature of the Observation

The observation centers on APL Healthcare Ltd.’s failure to conduct a comprehensive review of unexplained discrepancies or failures in any batch or its components to meet specified standards.

Specifically, the company fell short in ensuring that conclusions resulting from laboratory and production non-conformance investigations were scientifically justified and supported.

These conclusions play a pivotal role in decisions regarding the manufacturing and release of drug products.

The three instances noted in the observation are as follows:

Laboratory Investigation: The first instance pertains to a lapse in the laboratory investigation process.
Production Investigation: The second relates to shortcomings in the production investigation process.
Corrective and Preventive Action: The third instance highlights a failure to promptly initiate investigations and implement corrective and preventive actions to mitigate the likelihood of future non-conformances in the laboratory.

Aurobindo Pharma’s Response

Aurobindo Pharma is committed to addressing the observation promptly. The company has assured that it will collaborate closely with the USFDA, adhering to stipulated timelines, to rectify the identified procedural lapse.

This proactive approach reflects the company’s dedication to maintaining regulatory compliance and ensuring the highest standards of quality.

Impact and Future Steps

Queries regarding the potential impact of this observation on Aurobindo Pharma’s revenues and the anticipated timeline for resolution have been directed to the company.

However, responses were unavailable at the time of publication.

It remains imperative for Aurobindo Pharma to swiftly address this observation to safeguard its reputation and uphold regulatory compliance.

Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.